The Biology and Function of Tissue Inhibitor of Metalloproteinase 2 in the Lungs. (31st December 2022)

• Record Type: Journal Article
• Authors: Costanzo, Louis; Soto, Brian; Meier, Richard; Geraghty, Patrick
• Other Names: Kuwano Kazuyoshi Academic Editor.
• Is Part Of: Pulmonary medicine. Volume 2022(2022)
• Publication Date: 2022-12-31
• Subjects: Lungs -- Diseases -- Periodicals; Lung Diseases; Lungs -- Diseases; Electronic journals; Periodicals; Electronic journals -- Sciences; Electronic journals -- Medicine; Periodicals; 616.24
• DOI: 10.1155/2022/3632764
• Languages: English
• ISSNs: 2090-1836

Abstract

Abstract : Tissue inhibitors of matrix metalloproteinases (TIMP) are a family of four endogenous proteins that primarily function to inhibit the activities of proteases such as the matrix metalloproteinases (MMP). Altered MMP/TIMP ratios are frequently observed in several human diseases. During aging and disease progression, the extracellular matrix (ECM) undergoes structural changes in which elastin and collagens serve an essential role. MMPs and TIMPs significantly influence the ECM. Classically, elevated levels of TIMPs are suggested to result in ECM accumulation leading to fibrosis, whereas loss of TIMP responses leads to enhanced matrix proteolysis. Here, we outline the known roles of the most abundant TIMP, TIMP2, in pulmonary diseases but also discuss future perspectives in TIMP2 research that could impact the lungs. TIMP2 directly inhibits MMPs, in particular MMP2, but TIMP2 is also required for the activation of MMP2 through its interaction with MMP14. The protease and antiprotease imbalance of MMPs and TIMPs are extensively studied in diseases but recent discoveries suggest that TIMPs, specifically, TIMP2 could play other roles in aging and inflammation processes.